Sonoma Pharmaceuticals, Inc.

Equities

SNOA

US83558L2043

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
0.1566 USD -6.84% Intraday chart for Sonoma Pharmaceuticals, Inc. -6.73% -13.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference CI
Sector Update: Health Care Stocks Ease in Late Afternoon MT
Sector Update: Health Care MT
Top MIdday Decliners MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected MT
Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target MT
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board CI
Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller CI
Earnings Flash (SNOA) SONOMA PHARMACEUTICALS Reports Q4 Revenue $3M MT
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Sonoma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
Top Premarket Gainers MT
Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union CI
Sonoma Pharmaceuticals, Inc. Announces CFO Changes CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sonoma Pharmaceuticals Signs Distribution Deal With Daewoong Pharmaceutical to Sell Skin Products in South Korea MT
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea CI
Sector Update: Health Care Stocks Largely Sit Out Late Market Rebound MT
Sector Update: Health Care Stocks Still Lacking Traction MT
Chart Sonoma Pharmaceuticals, Inc.
More charts
Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1566 USD
Average target price
3.25 USD
Spread / Average Target
+1,975.35%
Consensus
  1. Stock Market
  2. Equities
  3. SNOA Stock
  4. News Sonoma Pharmaceuticals, Inc.
  5. Sonoma Pharmaceuticals Narrows Fiscal Q4 Loss, Revenue Higher; 2022 Revenue Drops Y/Y -- Shares Down After-Hours